Hallux Valgus Pipeline Insights, 2020

Hallux Valgus Pipeline Insights, 2020

“DelveInsight”
“Hallux Valgus Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hallux Valgus market. A detailed picture of the Hallux Valgus pipeline landscape is provided, which includes the disease overview and Hallux Valgus treatment guidelines.

Albany, US – DelveInsight launched a new report on Hallux Valgus Pipeline Insights, 2020

 

Some of the key facts of the report:-

The dynamics of Hallux Valgus market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. The launch of emerging therapies is expected during the forecast period of 2020-2030. The pipeline for Hallux Valgus (Bunion) is not very robust with Ipsen being the key player for the indication. Dysport by Ipsen is an injectable form of a botulinum neurotoxin type A, which is under phase II clinical developmental stage for Hallux Valgus. It is a substance derived from Clostridium bacteria producing BoNT-A which inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. It is currently under development for various other indications as well such as Vulvodynia (phase II), PUL spasticity (phase III) Glabellar lines (registered in China). The expected launch of emerging therapy such as abobotulinumtoxinA (Dysport) (Ipsen) is expected to change the treatment landscape of Hallux Valgus (Bunion) in the upcoming years. Ipsen has a patent protection for the treatment protocol of Hallux Valgus until 2038. Dysport has been recently approved in the United Kingdom in January 2020 for symptomatic treatment of upper limb spasticity in children with cerebral palsy. However, Dysport got approved in the United States in September 2019 for the similar indication as well.

Request for sample pages:- https://www.delveinsight.com/sample-request/hallux-valgus-pipeline-insight

 

Scope of the Report

  • The Hallux Valgus report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Hallux Valgus across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Hallux Valgus therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Hallux Valgus research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hallux Valgus.

 

 

Report highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Hallux Valgus.    
  • In the coming years, the Hallux Valgus market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Hallux Valgus R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Hallux Valgus treatment market. Several potential therapies for Hallux Valgus are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Hallux Valgus market size in the coming years.  
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Hallux Valgus) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

 

 

Request for sample pages:- :- https://www.delveinsight.com/sample-request/hallux-valgus-pipeline-insight

 

 

 Table of contents

1. Report Introduction

2. Hallux Valgus

2.1. Overview

2.2. History 

2.3. Hallux Valgus Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Hallux Valgus Diagnosis 

2.6.1. Diagnostic Guidelines

3. Hallux Valgus Current Treatment Patterns

3.1. Hallux Valgus Treatment Guidelines

4. Hallux Valgus – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Hallux Valgus companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Hallux Valgus Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Hallux Valgus Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Hallux Valgus Late Stage Products (Phase-III)

7. Hallux Valgus Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hallux Valgus Discontinued Products

13. Hallux Valgus Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Hallux Valgus Key Companies

15. Hallux Valgus Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Hallux Valgus Unmet Needs

18. Hallux Valgus Future Perspectives

19. Hallux Valgus Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

 

 

Related reports :-

Hallux Valgus Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’ s Hallux Valgus Market Insights, Epidemiology and Market Forecast 2030 report provides the detailed overview of disease and in depth understanding of disease epidemiology.

 

Hallux Valgus – Epidemiology Forecast to 2030

DelveInsight’s Hallux Valgus – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hallux Valgus in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/